Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adrian Marimon

Miami, FL Medical Doctor

NPI 1770718058 CMS profile 125401

11760 Sw 40Th Street, Suite 518, Miami, FL 33175

Open in the dashboard

General payments

$2,780

175 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$296,371 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Adrian Marimon of Miami, FL is reported in the CMS Open Payments database as having received $2,780 across 175 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $296,371 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $245 11
2024 General $403 26
2023 General $489 33
2022 General $687 43
2021 General $581 42
2020 General $168 8
2019 General $206 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adrian Marimon
  • Florida median
  • Middle half of Florida
  • National median

In program year 2025, general payments to Adrian Marimon were reported at $245. Among 84,641 Florida profiles paid that year, the median was $195 and the middle half received between $59 and $690.

Show as a table
Year Adrian Marimon Florida median Middle half National median
2019 $206 $197 $63–$719 $163
2020 $168 $126 $38–$436 $114
2021 $581 $151 $45–$537 $132
2022 $687 $175 $53–$607 $149
2023 $489 $183 $57–$637 $160
2024 $403 $185 $56–$647 $164
2025 $245 $195 $59–$690 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CooperSurgical, Inc. $791 66 payments
  2. AbbVie, Inc. $548 43 payments
  3. Hologic, LLC $165 7 payments
  4. Mission Pharmacal Company $134 8 payments
  5. Medical Device Business Services, Inc. $119 1 payment
  6. Evofem Biosciences, Inc. $86 4 payments
  7. Becton, Dickinson and Company $79 4 payments
  8. Ethicon US, LLC $76 2 payments
  9. Astellas Pharma US Inc $74 4 payments
  10. Exeltis, USA Inc. $72 3 payments
  11. Other $637 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,739 173 payments
  2. Education $41 2 payments
Products named General payments · program years 2019–2025
  1. Paragard $418 32 payments
  2. LO LOESTRIN FE $348 31 payments
  3. PARAGARD T 380A $348 33 payments
  4. LILETTA $189 12 payments
  5. THINPREP 2000 PROCESSOR $165 7 payments
  6. Aptima $165 7 payments
  7. CitraNatal $104 6 payments
  8. ORIAHNN $81 5 payments
  9. Balcoltra $65 5 payments
  10. BD Onclarity $63 3 payments
  11. Other $921 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record